ANGLE’s Successful Completion of AstraZeneca Assay Development Projects
ANGLE plc, a pioneering company in the field of liquid biopsy with innovative circulating tumour cell (CTC) solutions, has recently announced the successful completion of two significant development projects for AstraZeneca. These projects involved the creation of two new assays: the Parsortix-based Androgen Receptor (AR) assay and the DNA damage response (DDR) assay for the detection of micronuclei in CTCs.
The Parsortix-based Androgen Receptor (AR) Assay
The AR assay is designed to aid in the detection and analysis of prostate cancer cells. Androgens, which are male sex hormones, play a crucial role in the growth and development of prostate cancer. The AR assay uses ANGLE’s proprietary Parsortix technology to isolate CTCs from a patient’s blood sample, enabling researchers to study the expression of the AR protein in these cells. This information is essential for understanding the progression of the disease and developing targeted therapies.
The DNA Damage Response (DDR) Assay for Micronuclei Detection
The DDR assay focuses on the detection of micronuclei in CTCs as a measure of DNA damage. Micronuclei are fragments of chromatin that remain outside the nucleus after cell division. Their presence indicates DNA damage and can be used as a biomarker for various diseases, including cancer. ANGLE’s DDR assay utilizes the Parsortix system to isolate CTCs and subsequently identifies micronuclei in these cells. This technology can potentially help researchers monitor the efficacy of treatments that target DNA damage and contribute to the development of personalized medicine.
Eisai Phase 2 Pilot Study Results
In addition to the AstraZeneca collaborations, ANGLE has successfully completed a Phase 2 pilot study with Eisai, demonstrating the capability of the Parsortix system for real-time assessment of breast cancer patient HER2 status. HER2 is a protein that plays a role in the growth and spread of breast cancer. Accurately measuring HER2 status is crucial for selecting appropriate treatments and monitoring their effectiveness. ANGLE’s Parsortix-based HER2 assay can potentially offer a more efficient and cost-effective alternative to traditional methods, such as invasive biopsies.
Implications for Patients and the World
These developments have significant implications for patients and the world. Firstly, the successful completion of these assay development projects and the Eisai contract demonstrates the applicability of ANGLE’s Parsortix technology in various cancer research and clinical settings. The ability to detect and analyze specific markers in CTCs, such as AR expression, HER2 status, and DNA damage, can lead to more effective and personalized therapies, ultimately improving patient outcomes.
Conclusion
ANGLE plc’s innovative work in the field of liquid biopsy and CTC analysis continues to yield significant results. The successful completion of the AstraZeneca assay development projects and the Eisai contract signify the potential for ANGLE’s Parsortix technology to contribute to the advancement of cancer research and the development of personalized treatments. As research in this area progresses, we can expect to see more applications of these technologies, leading to improved patient care and outcomes.
- ANGLE plc completes AstraZeneca assay development projects for AR and DDR.
- Parsortix technology isolates CTCs for analysis of AR expression and DNA damage.
- Phase 2 pilot study with Eisai demonstrates real-time assessment of breast cancer patient HER2 status.
- Implications for personalized medicine and improved patient outcomes.
